Investigational / not FDA-approved

Eloralintide

Selective long-acting amylin receptor agonist (LY3841136) — investigational obesity candidate.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Eloralintide (developmental code LY3841136) is a selective, long-acting amylin receptor agonist (development literature emphasizes preferential AMY1R activity versus non-selective amylin analogues). PubChem CID 175663130; formula C201H319N49O65S2 / MW ~4526; CAS 2883634-40-8. It has no approved drug indication. Off-label does not apply. There is no label to be off of. It is not cagrilintide (a different long-acting amylin analogue, often studied with semaglutide as CagriSema), not semaglutide, and not a GLP-1/GIP dual or triple agonist. Identity confidence for the named clinical object is high on the primary Lilly trial reports below; broader cardiometabolic / phase 3 extrapolation remains thin. Always pair the name with LY3841136 in searches — bare LY queries explode.

Bottom line

PubMed holds a discovery-to–phase 1 proof-of-concept package and a 48-week phase 2 randomized obesity trial without type 2 diabetes. Those are investigational human objects. Secondary reviews and network meta-analyses discuss the amylin class; they do not create a label. No dedicated cardiovascular-outcomes trial for eloralintide appears in this set. Honest grade: therapeutic evidence is real but thin beyond phase 2 obesity.

Papers

Investigational — discovery / phase 1

PMID 41109426 — Briere 2025

Tested: discovery pharmacology of eloralintide (LY3841136) through preclinical models and a phase 1 single-ascending-dose proof-of-concept trial in healthy participants with overweight (randomized, placebo-controlled).

Does not show: confirmatory phase 2/3 labeled obesity treatment, or equivalence to cagrilintide.

PMID 41559929 — Bhattachar 2026

Tested: phase 1 proof-of-concept report for eloralintide as a selective, long-acting amylin receptor agonist for treatment of obesity.

Does not show: the 48-week phase 2 Billings object by itself, or an approved indication. (Related early-human package to Briere; mark as phase 1 POC, not phase 2.)

Investigational — obesity (phase 2)

PMID 41207310 — Billings 2025

Tested: once-weekly injectable eloralintide versus placebo for percent body-weight change over 48 weeks in adults with obesity or overweight plus a weight-related comorbidity, without type 2 diabetes (multicentre, double-blind, randomised phase 2).

Does not show: a labeled obesity indication, a type 2 diabetes population result, a CagriSema combination claim, or a dedicated CVOT.

Secondary / class context (not primary eloralintide efficacy)

PMID 42745233 — Sigalov 2026

Tested: literature review of emerging cardiovascular implications of selective amylin receptor agonism with focus on early eloralintide clinical signals.

Does not show: a cardiovascular-outcomes trial, or a labeled cardiometabolic indication.

PMID 41747885 — Bailey 2026

Tested: review of long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (class context).

Does not show: a new eloralintide primary randomized result.

PMID 42452898 — Alhazmi 2026

Tested: review of amylin analogs as an emerging weight-loss therapy class, summarizing experimental data and early-phase clinical trials.

Does not show: confirmatory phase 3 eloralintide efficacy, or identity between eloralintide and cagrilintide.

PMID 42586227 — Fischer 2026

Tested: review of amylin-based pharmacotherapy beyond GLP-1 for weight-loss drug development.

Does not show: a new primary eloralintide trial object.

PMID 42175595 — Kamrul-Hasan 2026

Tested: network meta-analysis of novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes.

Does not show: a head-to-head labeled claim; indirect comparisons are not single-trial proof for eloralintide alone.

What is not established

An approved obesity or diabetes indication. That eloralintide equals cagrilintide or CagriSema. A type 2 diabetes primary program result in this drawer. A dedicated major-adverse-cardiovascular-events trial. Product identity between laboratory or unlabeled material and the LY3841136 trial product. Phase 3 confirmatory evidence as a substitute for the phase 2 Billings object.

Selected sources

41109426 41559929 41207310 42745233 41747885 42452898 42586227 42175595

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.